Article Information
History
- August 20, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Miriam Sturkenboom, professor in Real World Evidence*,1,2,
- Davide Messina, datascientist3,
- Olga Paoletti, statistician4,
- Airam de Burgos-Gonzalez, medical epidemiologist5,
- Patricia García-Poza, senior pharmacoepidemiologist5,
- Consuelo Huerta, senior pharmacoepidemiologist5,
- Ana Llorente- García, pharmacoepidemiologist5,
- Mar Martin-Perez, pharmacoepidemiologist5,
- Maria Martinez,
- Ivonne Martin, Biostatistician1,
- Jetty Overbeek, senior pharmacoepidemiologist6,
- Marc Padros-Goossens, senior scientific programmer1,
- Patrick Souverein, senior pharmacoepidemiologist7,
- Karin Swart, pharmacoepidemiologist6,
- Olaf Klungel, professor in methods of pharmacoepidemiology7 and
- Rosa Gini, senior mathematician, data scientist3
- 1Department of Datascience & Biostatistics, Julius Center for Health Sciences and Primary Health. University Medical Center Utrecht, The Netherlands
- 2Vaccine Monitoring Collaboration for Europe, Brussels, Belgium
- 3Agenzia Regionale di Sanita’, Florence Toscana, Italy
- 4Agenzia Regionale di Sanitá, Florence Toscana, Italy
- 5Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain
- 6PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands
- 7Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
- ↵*[corresponding author] Address: University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, E-mail: m.c.j.sturkenboom{at}umcutrecht.nl
Posted August 20, 2022.
Cohort monitoring of 29 Adverse Events of Special Interest prior to and after COVID-19 vaccination in four large European electronic healthcare data sources
